RS65395B1 - Stabilan tečni farmaceutski preparat - Google Patents

Stabilan tečni farmaceutski preparat

Info

Publication number: RS65395B1
Authority: RS; Serbia
Prior art keywords: pharmaceutical preparation; liquid pharmaceutical; stable liquid; stable; preparation
Prior art date: 2016-06-30

Application number

RS20240425A

Other languages

English (en)

Inventor

Joon Won Lee

Won Yong Han

Su Jung Kim

Jun Seok Oh

So Young Kim

Su Hyeon Hong

Yeon Kyeong Shin

Original Assignee

Celltrion Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-06-30

Filing date

2017-06-28

Publication date

2024-04-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60787364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS65395(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2017-06-28 Application filed by Celltrion Inc filed Critical Celltrion Inc

2024-04-30 Publication of RS65395B1 publication Critical patent/RS65395B1/sr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Mycology (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Dermatology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Transplantation (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Infusion, Injection, And Reservoir Apparatuses (AREA)

RS20240425A 2016-06-30 2017-06-28 Stabilan tečni farmaceutski preparat RS65395B1 (sr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
KR20160083039		2016-06-30
EP17820536.5A EP3479819B1 (en)	2016-06-30	2017-06-28	Stable liquid pharmaceutical preparation
PCT/KR2017/006855 WO2018004260A1 (ko)	2016-06-30	2017-06-28	안정한 액체 약제학적 제제

Publications (1)

Publication Number	Publication Date
RS65395B1 true RS65395B1 (sr)	2024-04-30

Family

ID=60787364

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RS20240425A RS65395B1 (sr)	2016-06-30	2017-06-28	Stabilan tečni farmaceutski preparat

Country Status (40)

Country	Link
US (3)	US11951207B2 (sr)
EP (2)	EP4338752A3 (sr)
JP (2)	JP7082070B2 (sr)
KR (3)	KR20180003452A (sr)
CN (1)	CN109310628A (sr)
AU (2)	AU2017287743C1 (sr)
BR (1)	BR112018076377A2 (sr)
CA (1)	CA3028238C (sr)
CL (1)	CL2018003662A1 (sr)
CO (1)	CO2018013689A2 (sr)
CR (1)	CR20180599A (sr)
CU (1)	CU24561B1 (sr)
DK (1)	DK3479819T5 (sr)
DO (1)	DOP2018000290A (sr)
EA (1)	EA201892653A1 (sr)
EC (1)	ECSP18093651A (sr)
ES (1)	ES2975782T3 (sr)
FI (1)	FI3479819T3 (sr)
GE (1)	GEP20217249B (sr)
HR (1)	HRP20240426T1 (sr)
HU (1)	HUE066142T2 (sr)
IL (1)	IL263630B2 (sr)
JO (1)	JOP20180125B1 (sr)
LT (1)	LT3479819T (sr)
MA (1)	MA45562B1 (sr)
MD (1)	MD3479819T2 (sr)
MX (1)	MX2018015960A (sr)
NI (1)	NI201800139A (sr)
PE (1)	PE20190448A1 (sr)
PH (1)	PH12018502670A1 (sr)
PL (1)	PL3479819T3 (sr)
PT (1)	PT3479819T (sr)
RS (1)	RS65395B1 (sr)
SG (1)	SG11201811320YA (sr)
SI (1)	SI3479819T1 (sr)
TN (1)	TN2018000443A1 (sr)
TW (1)	TWI736643B (sr)
UA (1)	UA122610C2 (sr)
WO (1)	WO2018004260A1 (sr)
ZA (1)	ZA201808476B (sr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8883146B2 (en)	2007-11-30	2014-11-11	Abbvie Inc.	Protein formulations and methods of making same
CA3049857A1 (en)	2017-01-11	2018-07-19	Celltrion Inc.	Stable liquid formulation
KR20190024572A (ko) *	2017-08-30	2019-03-08	(주)셀트리온	TNFα 관련 질환을 치료하기 위한 피하 투여 요법
WO2020060192A1 (ko) *	2018-09-18	2020-03-26	삼성바이오에피스 주식회사	고농도의 계면활성제를 포함하는 트라스투주맙 안정화 액체 제제
MX2021004146A (es) *	2018-10-10	2021-06-08	Astellas Pharma Inc	Composicion farmaceutica que contiene complejo de fragmento fab de anticuerpo antihumano con sitio marcado.
MA55033A (fr)	2019-02-18	2021-12-29	Lilly Co Eli	Formulation d'anticorps thérapeutique
CN111686247B (zh) *	2019-03-13	2022-07-29	苏州康乃德生物医药有限公司	包含人白介素-4受体α的抗体的液体组合物
US20230203147A1 (en) *	2019-03-18	2023-06-29	Alvotech Hf	Aqueous formulations of tnf-alpha antibodies in high concentrations
CN110095615A (zh) *	2019-05-27	2019-08-06	山东艾科达生物科技有限公司	一种测定超敏c反应蛋白含量的试剂盒
CN110585430B (zh) *	2019-09-29	2023-09-08	华博生物医药技术（上海）有限公司	一种人源化抗人il-17a单克隆抗体的药物组合物
US20230115267A1 (en) *	2020-03-13	2023-04-13	Samsung Bioepis Co., Ltd.	Pharmaceutical liquid composition having increased stability
AU2021251661A1 (en) *	2020-04-06	2022-11-03	Forty Seven, Inc.	Antibody formulation
WO2023043232A1 (ko) *	2021-09-16	2023-03-23	주식회사 에이프로젠	항-TNFα 항체를 포함하는 약제학적 조성물
CN113940997B (zh) *	2021-12-21	2022-04-08	迈威(上海)生物科技股份有限公司	一种双特异性抗体的稳定制剂
CN118369117A (zh) *	2021-12-28	2024-07-19	山东先声生物制药有限公司	一种抗tnfr2抗体药物组合物
WO2024124177A2 (en) *	2022-12-09	2024-06-13	Xentria, Inc.	Methods of treating sarcoidosis with a tnf-α antibody and associated compositions and methods

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4861335A (en)	1985-07-26	1989-08-29	Duoject Medical Systems Inc.	Syringe
US5085642A (en)	1989-07-17	1992-02-04	Survival Technology, Inc.	Conveniently carried frequent use autoinjector
US6284471B1 (en)	1991-03-18	2001-09-04	New York University Medical Center	Anti-TNFa antibodies and assays employing anti-TNFa antibodies
EP0768902B1 (en)	1992-11-19	1998-07-15	Tebro S.A.	Disposable auto-injector for prefilled syringes
DE4438360C2 (de)	1994-10-27	1999-05-20	Schott Glas	Vorfüllbare partikelarme, sterile Einmalspritze für die Injektion von Präparaten und Verfahren zu ihrer Herstellung
JO3000B1 (ar) *	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
SI2390267T1 (sl) *	2005-06-07	2013-07-31	Esbatech - A Novartis Company Llc	Stabilna in topna protitelesa, ki inhibirajo TNF(alfa)
DK2307454T3 (en)	2008-06-25	2017-04-24	Esbatech Alcon Biomed Res Unit	Stable and soluble antibodies that inhibit VEGF
CN102458469B (zh)	2009-05-04	2014-12-24	艾伯维生物技术有限公司	人抗TNF-α抗体的稳定高蛋白质浓度制剂
US9345661B2 (en)	2009-07-31	2016-05-24	Genentech, Inc.	Subcutaneous anti-HER2 antibody formulations and uses thereof
JP6113756B2 (ja) *	2012-01-23	2017-04-12	リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	抗ａｎｇ２抗体を含有する安定化製剤
US10316095B2 (en) *	2012-02-16	2019-06-11	Santarus, Inc.	Antibody formulations
NZ629261A (en) *	2012-03-07	2017-08-25	Cadila Healthcare Ltd	Pharmaceutical formulations of tnf-alpha antibodies
JP2015519382A (ja)	2012-06-12	2015-07-09	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	治療用抗体のための医薬処方物
FR2994390B1 (fr)	2012-08-10	2014-08-15	Adocia	Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
US9592297B2 (en)	2012-08-31	2017-03-14	Bayer Healthcare Llc	Antibody and protein formulations
LT2892550T (lt)	2012-09-07	2020-04-10	Coherus Biosciences, Inc.	Stabilios adalimumabo vandeninės kompozicijos
FR2995214B1 (fr)	2012-09-10	2014-11-21	Adocia	Solution a viscosite reduite de proteine a concentration elevee
SG11201502816YA (en) *	2012-10-12	2015-05-28	Agency Science Tech & Res	Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics
MX2015004668A (es) *	2012-10-25	2015-07-23	Medimmune Llc	Formulacion estable de anticuerpos de baja viscosidad.
US20140161790A1 (en) *	2012-11-19	2014-06-12	Xencor, Inc.	Engineered immunoglobulins with extended in vivo half-life
CA2898262A1 (en)	2013-01-24	2014-07-31	Glaxosmithkline Intellectual Property Development Limited	Tnf-alpha antigen-binding proteins
CA2926588C (en)	2013-10-16	2020-07-21	Oncobiologics, Inc.	Buffer formulations for enhanced antibody stability
CN104666242B (zh)	2013-11-26	2018-01-02	信达生物制药(苏州)有限公司	一种稳定的抗TNF‑α抗体制剂及其用途
CN104707146B (zh)	2013-12-16	2019-04-16	浙江海正药业股份有限公司	一种含有阿达木单抗的药物组合物
IN2014MU01248A (sr) *	2014-04-02	2015-10-09	Intas Pharmaceuticals Ltd
RS55548B1 (sr)	2014-05-23	2017-05-31	Ares Trading Sa	Tečni farmaceutski sastav
HUP1400510A1 (hu) *	2014-10-28	2016-05-30	Richter Gedeon Nyrt	Gyógyászati TNFalfa ellenes antitest készítmény
US20170360929A1 (en)	2014-12-23	2017-12-21	Pfizer Inc.	Stable aqueous antibody formulation for anti tnf alpha antibodies
MX2017010400A (es)	2015-02-13	2017-11-28	Sanofi Sa	Formulacion liquida estable para anticuerpos monoclonales.
AR118191A1 (es)	2019-02-28	2021-09-22	Celltrion Inc	MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNFa

2017
- 2017-06-28 RS RS20240425A patent/RS65395B1/sr unknown
- 2017-06-28 MA MA45562A patent/MA45562B1/fr unknown
- 2017-06-28 LT LTEPPCT/KR2017/006855T patent/LT3479819T/lt unknown
- 2017-06-28 JO JOP/2018/0125A patent/JOP20180125B1/ar active
- 2017-06-28 CA CA3028238A patent/CA3028238C/en active Active
- 2017-06-28 FI FIEP17820536.5T patent/FI3479819T3/fi active
- 2017-06-28 HR HRP20240426TT patent/HRP20240426T1/hr unknown
- 2017-06-28 PL PL17820536.5T patent/PL3479819T3/pl unknown
- 2017-06-28 BR BR112018076377-2A patent/BR112018076377A2/pt active Search and Examination
- 2017-06-28 HU HUE17820536A patent/HUE066142T2/hu unknown
- 2017-06-28 MD MDE20190562T patent/MD3479819T2/ro unknown
- 2017-06-28 EP EP24152383.6A patent/EP4338752A3/en active Pending
- 2017-06-28 UA UAA201812485A patent/UA122610C2/uk unknown
- 2017-06-28 TN TNP/2018/000443A patent/TN2018000443A1/en unknown
- 2017-06-28 CU CU2018000154A patent/CU24561B1/es unknown
- 2017-06-28 CN CN201780036776.0A patent/CN109310628A/zh active Pending
- 2017-06-28 KR KR1020170081814A patent/KR20180003452A/ko not_active Application Discontinuation
- 2017-06-28 PT PT178205365T patent/PT3479819T/pt unknown
- 2017-06-28 SG SG11201811320YA patent/SG11201811320YA/en unknown
- 2017-06-28 PE PE2018003247A patent/PE20190448A1/es unknown
- 2017-06-28 SI SI201731501T patent/SI3479819T1/sl unknown
- 2017-06-28 CR CR20180599A patent/CR20180599A/es unknown
- 2017-06-28 EP EP17820536.5A patent/EP3479819B1/en active Active
- 2017-06-28 EA EA201892653A patent/EA201892653A1/ru unknown
- 2017-06-28 WO PCT/KR2017/006855 patent/WO2018004260A1/ko active Application Filing
- 2017-06-28 TW TW106121657A patent/TWI736643B/zh active
- 2017-06-28 MX MX2018015960A patent/MX2018015960A/es unknown
- 2017-06-28 AU AU2017287743A patent/AU2017287743C1/en active Active
- 2017-06-28 GE GEAP201714966A patent/GEP20217249B/en unknown
- 2017-06-28 DK DK17820536.5T patent/DK3479819T5/da active
- 2017-06-28 ES ES17820536T patent/ES2975782T3/es active Active
- 2017-06-28 US US16/310,585 patent/US11951207B2/en active Active
- 2017-06-28 JP JP2018565705A patent/JP7082070B2/ja active Active
2018
- 2018-07-25 KR KR1020180086393A patent/KR102229274B1/ko active IP Right Grant
- 2018-12-10 IL IL263630A patent/IL263630B2/en unknown
- 2018-12-14 ZA ZA2018/08476A patent/ZA201808476B/en unknown
- 2018-12-18 CL CL2018003662A patent/CL2018003662A1/es unknown
- 2018-12-18 DO DO2018000290A patent/DOP2018000290A/es unknown
- 2018-12-18 EC ECSENADI201893651A patent/ECSP18093651A/es unknown
- 2018-12-18 NI NI201800139A patent/NI201800139A/es unknown
- 2018-12-18 PH PH12018502670A patent/PH12018502670A1/en unknown
- 2018-12-18 CO CONC2018/0013689A patent/CO2018013689A2/es unknown
2020
- 2020-02-20 AU AU2020201249A patent/AU2020201249B2/en active Active
2021
- 2021-03-05 KR KR1020210029750A patent/KR102397713B1/ko active IP Right Grant
2022
- 2022-05-26 JP JP2022086449A patent/JP7405324B2/ja active Active
2024
- 2024-02-06 US US18/434,346 patent/US20240269069A1/en active Pending
- 2024-03-01 US US18/593,012 patent/US20240269071A1/en active Pending

Also Published As

Publication number	Publication date
PE20190448A1 (es)	2019-03-29
HRP20240426T1 (hr)	2024-06-21
CA3028238A1 (en)	2018-01-04
LT3479819T (lt)	2024-04-25
PT3479819T (pt)	2024-04-15
TWI736643B (zh)	2021-08-21
CO2018013689A2 (es)	2019-01-18
US20240269071A1 (en)	2024-08-15
AU2020201249B2 (en)	2021-07-15
CL2018003662A1 (es)	2019-03-15
US20240269069A1 (en)	2024-08-15
JP7082070B2 (ja)	2022-06-07
CU20180154A7 (es)	2019-08-06
CU24561B1 (es)	2022-01-13
CN109310628A (zh)	2019-02-05
MD3479819T2 (ro)	2024-07-31
IL263630A (en)	2019-01-31
US11951207B2 (en)	2024-04-09
EP4338752A3 (en)	2024-04-03
MA45562B1 (fr)	2024-05-31
TN2018000443A1 (en)	2020-06-15
MA45562A (fr)	2019-05-08
KR20180003452A (ko)	2018-01-09
JP7405324B2 (ja)	2023-12-26
EP3479819A1 (en)	2019-05-08
AU2017287743B2 (en)	2020-01-30
US20210000743A1 (en)	2021-01-07
NI201800139A (es)	2019-03-25
NZ748101A (en)	2020-11-27
KR102397713B1 (ko)	2022-05-13
AU2017287743A1 (en)	2018-11-22
AU2017287743C1 (en)	2020-10-01
CR20180599A (es)	2019-04-09
ECSP18093651A (es)	2019-01-31
EP4338752A2 (en)	2024-03-20
WO2018004260A1 (ko)	2018-01-04
JP2019525902A (ja)	2019-09-12
MX2018015960A (es)	2019-03-21
ZA201808476B (en)	2020-08-26
FI3479819T3 (fi)	2024-04-17
KR20180097471A (ko)	2018-08-31
PH12018502670A1 (en)	2019-10-07
JOP20180125B1 (ar)	2022-09-15
IL263630B2 (en)	2023-06-01
HUE066142T2 (hu)	2024-07-28
SG11201811320YA (en)	2019-01-30
AU2020201249A1 (en)	2020-03-12
DK3479819T5 (da)	2024-09-09
CA3028238C (en)	2024-01-02
DOP2018000290A (es)	2019-02-15
SI3479819T1 (sl)	2024-06-28
UA122610C2 (uk)	2020-12-10
KR20210042052A (ko)	2021-04-16
JOP20180125A1 (ar)	2019-01-30
EP3479819A4 (en)	2020-02-26
DK3479819T3 (da)	2024-04-15
BR112018076377A2 (pt)	2019-03-26
EP3479819B1 (en)	2024-01-24
JP2022122941A (ja)	2022-08-23
TW201806617A (zh)	2018-03-01
KR102229274B1 (ko)	2021-03-18
ES2975782T3 (es)	2024-07-15
GEP20217249B (en)	2021-04-26
EA201892653A1 (ru)	2019-05-31
PL3479819T3 (pl)	2024-07-01

Publication	Publication Date	Title
ZA201808476B (en)	2020-08-26	Stable liquid pharmaceutical preparation
IL282481A (en)	2021-06-30	A liquid pharmaceutical preparation
ZA201901590B (en)	2020-10-28	Liquid pharmaceutical composition
ZA201901736B (en)	2020-11-25	Liquid pharmaceutical composition
IL277241A (en)	2020-10-29	A liquid pharmaceutical preparation
HK1257026A1 (zh)	2019-10-11	液體藥物組合物
ZA201907313B (en)	2021-05-26	Stable liquid pharmaceutical composition
HK1257435A1 (zh)	2019-10-18	液態藥物製劑
HK1244685A1 (zh)	2018-08-17	液體藥物組合物
IL253572A0 (en)	2017-09-28	A liquid pharmaceutical preparation